USFDA nod to Zydus Lifesciences Famotidine Tablets
It is used to prevent and treat heartburn and other symptoms caused by excessive acid in the stomach (acid indigestion).
Ahmedabad: Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Famotidine Tablets in the strengths of 20mg and 40mg (USRLD: Pepcid).
Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid in the stomach. It is used to prevent and treat heartburn and other symptoms caused by excessive acid in the stomach (acid indigestion).
The drug will be manufactured at group's drug formulation facility at SEZ, Ahmedabad.
Famotidine Tablet has a market size of USD 67 mn (as per IQVIA MAT April 2022). The group now has 315 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences Chemotherapy drug Pemetrexed gets USFDA okay
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.